3rd Quarter - Report

ASTELLAS PHARMA US, INC. for ASTELLAS PHARMA US, INC.

Firm
Client
Income
—
Expenses
$550,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
JOSEPH DEVANEY —
VALARIE MOLAISON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1416 (116th)

Health Issues HCR

Value of Prescription Drugs, Senate & House. Issues related to Bayh-Dole Act (Pub. L. 96-517). Issues related to pharmaceutical supply chain management, S.3537 Protecting Our Pharmaceutical Supply Chain. Health care issues related to the National Defense Authorization Act (H.R. 2500, S. 1790).

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
JOSEPH DEVANEY —
VALARIE MOLAISON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2500 (116th), S. 3537 (116th), S. 1790 (116th)

Medicare/Medicaid MMM

Issues related to Medicare Part D policies, including patient access,non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures.

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
JOSEPH DEVANEY —
VALARIE MOLAISON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 2543 (116th), H.R. 19 (116th), H.R. 3 (116th), S. 3129 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.